Bridging the Governance Gap in Canadian Health AI
The recent insights from MLT Aikins regarding the integration of Artificial Intelligence (AI) in Canadian health care underscore a critical reality: while the technological potential for AI scribes and predictive analytics is transformative, the regulatory “void” left by the prorogation of Bill C-27 (and the Artificial Intelligence and Data Act) creates a high-stakes environment for health-care providers.
At Newport Thomson, we believe waiting for a comprehensive federal framework is a luxury health organizations cannot afford. As this article correctly identifies, privacy remains the primary battleground. For organizations, including community-led health initiatives, the focus must shift from “waiting for the law” to active governance.
Key Takeaways & The Newport Thomson Perspective
1. The Accountability Shift
The article highlights that healthcare providers cannot shift responsibility to AI. We take this further: Accountability is not just a legal liability; it is a brand asset. Whether you are a large hospital or a specialized association (such as the African Caribbean Kidney Association), validating AI outputs through human oversight is the only way to maintain the “Trust Equity” built with patients over decades. It takes years to build that trust and only takes a few mis-informed actions to destroy it.
2. Privacy by Design in the Absence of AIDA
With AIDA currently off the table, the reliance on PIPEDA and provincial health acts (like PHIPA) means that the burden of proof for “informed consent” has never been higher. Newport Thomson advocates for a “Consent-First Architecture”, ensuring that if an app or tool uses patient data for machine learning, the value proposition to the patient is as clear as the privacy safeguard.
3. Vendor Due Diligence is the New Compliance
We strongly agree with the emphasis on vendor agreements. In our experience, many health AI tools are built on third-party LLMs that may not natively align with Canadian health privacy standards. Organizations must ensure that “standard technology provisions” are replaced with data-residency and purpose-limitation clauses that specifically protect personal health information from being used to train global models without authorization.
Strategic Recommendation
The MLT Aikins piece serves as a timely reminder that the intersection of health care and AI is where “Legal Risk” meets “Operational Opportunity.”
For our partners and clients, Newport Thomson’s approach is simple: Govern for the most stringent standard. By implementing robust AI governance policies and privacy impact assessments (PIAs) now, organizations don’t just mitigate risk, they build a foundation of trust that makes them the preferred choice for patients and investors alike.
